Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration - Redeye
Bildkälla: Stockfoto

Corline Biomedical (Q1 Review): Encouraging signs of commercial acceleration - Redeye

Redeye provides an update following Corline’s Q1 2026 report. We are positive on the sales development, which shows early signs of a sales ramp-up. We maintain a positive view on Corline’s outlook and expect a clearer sales ramp-up in the coming quarters. We have only made minor fine-tuning to our estimates, leaving our fair value range unchanged.

Redeye provides an update following Corline’s Q1 2026 report. We are positive on the sales development, which shows early signs of a sales ramp-up. We maintain a positive view on Corline’s outlook and expect a clearer sales ramp-up in the coming quarters. We have only made minor fine-tuning to our estimates, leaving our fair value range unchanged.
Börsvärldens nyhetsbrev